Company Dossier · Health Care
Becton Dickinson
- S&P 500
- Russell 1000
What Becton Dickinson is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $22.5 billion, up 18% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to September 30, 2025: $2.67 billion, down 14% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 30, 2026: $0.75 billion, up 10% from a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to September 30, 2025: $1.00 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (August 6, 2026): sentiment 0.70 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.85 of 1.Palanor Discourse
- Guidance in the last 90 days: 1 outlook figure raised, 0 lowered, 0 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed November 25, 2025): 4 risk factors added, 1 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q3 2026: $1.3 million on the open market.SEC Form 4
- 1,448 institutional managers reported a position at June 30, 2026 (−29 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 70 (92 a year earlier).U.S. Department of Labor (OFLC)
Risk events (12 months): 1 — latest OSHA inspection, Dec 1, 2025 →
Company Posture
How Company Posture is measured →What Becton Dickinson is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.
Steady · Confident
Expanding ↔ Retrenching
Steady
- Capital spending74th pct
- Debt raised—
- Buybacks vs capex19th pct
- Hiring filings73rd pct
- Deals and private raises49th pct
- Patent publications49th pct
Confident ↔ Hedging
Confident
- Call sentiment77th pct
- Call confidence81st pct
- Guidance changes95th pct
- Risk factors added11th pct
- Insider open-market trades31st pct
- + Guidance changes
- + Call sentiment
- + Call confidence
Pressure
Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).
- Fails-to-deliver83rd pct
- Stress filings48th pct
Credit
How these are built →Becton Dickinson's borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.
Debt on the balance sheet
$16.8B
- Due within a year $3.3B
- Longer term $13.5B
- Default point $10.1B (short + ½ long)
Finance leases included · Jun 30, 2026 filing
Bonds priced, last 12 months
None
U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.
| Priced | Amount | Coupon | Matures | Spread | Yield |
|---|---|---|---|---|---|
| May 11, 2026 | €600M | 3.855% | 2033 (7y) | +101bp | 3.855% |
| Jun 4, 2024 | €1B | 3.828% | 2032 (8y) | +135bp | 3.828% |
| Jun 4, 2024 | €800M | 4.029% | 2036 (12y) | +142bp | 4.029% |
| Jun 4, 2024 | $600M | 5.081% | 2029 (5y) | +75bp | 5.081% |
| Feb 5, 2024 | €750M | 3.519% | 2031 (7y) | +132bp | 3.519% |
| Feb 5, 2024 | $550M | 5.110% | 2034 (10y) | +95bp | 5.110% |
| Feb 5, 2024 | $625M | 4.874% | 2029 (5y) | +75bp | 4.874% |
From the pricing term sheets Becton Dickinson filed with the SEC. Spread is to the benchmark Treasury (or Bund, Gilt) at pricing.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
In the news
Headlines that name Becton Dickinson, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.
- NeutralNotable healthcare headlines for the week: Novavax, Moderna and Becton Dickinson in focus
seekingalpha.com · via Marketaux · Oct 11, 2026
- NeutralBecton, Dickinson and Co. (BDX) Dividend Stock Analysis
dividend-growth-stocks.com · via Marketaux · Oct 9, 2026
- NeutralBecton Dickinson (BDX) to Invest $3 Billion in U.S. Medical Supply Production
gurufocus.com · via Marketaux · Oct 6, 2026
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 20, 2026LobbyingLobbying report (BECTON, DICKINSON AND COMPANY)first_quarter 2026 · $0.8 million
- Oct 20, 2026LobbyingLobbying report (BECTON, DICKINSON AND COMPANY)third_quarter 2026 · $0.4 million
- Oct 20, 2026LobbyingLobbying report (BGR GOVERNMENT AFFAIRS)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (BROWNSTEIN HYATT FARBER SCHRECK, LLP)third_quarter 2026 · $0.1 million
- Oct 20, 2026Patent
- Oct 20, 2026Patent
- Oct 20, 2026Patent
- Oct 20, 2026Patent
- Oct 20, 2026Patent
- Oct 14, 2026LobbyingLobbying report (DCI GROUP, L.L.C.)third_quarter 2026 · $0.1 million
- Sep 22, 2026LobbyingLobbying report (BROWNSTEIN HYATT FARBER SCHRECK, LLP)third_quarter 2026
- Jul 22, 20268-KDirector or officer changeItem 5.02
- Jul 20, 2026LobbyingLobbying report (BGR GOVERNMENT AFFAIRS)second_quarter 2026 · $0.1 million
- Jul 20, 2026LobbyingLobbying report (BECTON, DICKINSON AND COMPANY)second_quarter 2026 · $0.6 million
- May 20, 20268-KMaterial agreement signedItem 1.01
- May 7, 20268-KDirector or officer changeItem 5.02
- Apr 9, 20268-KDirector or officer changeItem 5.02
- Feb 9, 20268-KMaterial agreement signedItem 1.01
- Feb 9, 20268-KDirector or officer changeItem 5.02
- Jan 30, 20268-KShareholder vote resultsItem 5.07
- Jan 30, 20268-KDirector or officer changeItem 5.02
- Dec 1, 20258-KDirector or officer changeItem 5.02
- Dec 1, 2025Risk event
- Nov 25, 202510-KAnnual report (10-K)4 risk factors added, 1 removed
- Nov 17, 20258-KDirector or officer changeItem 5.02
- Oct 15, 20258-KDirector or officer changeItem 5.02
- Sep 18, 20258-KMaterial agreement signedItem 1.01
- Sep 17, 2025Risk event
- Sep 16, 2025Risk event
- Aug 7, 2025Risk event
- Aug 7, 2025Risk event
- Jul 14, 20258-KMaterial agreement signedItem 1.01
- May 20, 2025Risk event
- May 20, 2025Risk event
- Mar 27, 20258-KDirector or officer changeItem 5.02
- Jan 31, 20258-KShareholder vote resultsItem 5.07
- Jan 10, 20258-KDirector or officer changeItem 5.02
- Nov 27, 202410-KAnnual report (10-K)0 risk factors added, 2 removed
- Nov 21, 202310-KAnnual report (10-K)0 risk factors added, 0 removed
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Boston Scientific BSX | $21.0B | $3.6B | Jun 30, 2026 |
| GE HealthCare GEHC | $21.0B | — | Mar 31, 2026 |
| Stryker Corporation SYK | $25.8B | $4.7B | Jun 30, 2026 |
| Medtronic MDT | $37.5B | $6.1B | Jul 31, 2026 |
| Baxter International BAX | $11.5B | — | Jun 30, 2026 |
| Intuitive Surgical ISRG | $11.0B | $3.2B | Jun 30, 2026 |
| Zimmer Biomet ZBH | $8.5B | $1.5B | Jun 30, 2026 |
| Edwards Lifesciences EW | $6.5B | $1.4B | Jun 30, 2026 |